ASEP licenses anti-biofilm peptide tech to Bondent

Executive Summary

• ASEP Medical Holdings entered a patent‑licensing agreement with Shanghai Bondent Technology to develop and commercialize an oral rinse using ASEP’s anti‑biofilm peptide technology in China and multiple other Asian territories.
• Under the deal, Bondent will handle development, clinical trials, and marketing; ASEP (via ABT Innovations) will receive a 10 % royalty on all sales of the product.
• COO/Corporate Secretary Timothy Murphy announced his resignation effective 31 Oct 2025 and will move to a board role at Sepset Biosciences to focus on the sepsis diagnostic platform.

Key Details

• Agreement Scope: Patent licensing for ASEP’s anti‑biofilm peptide technology; Bondent granted rights in PRC, Taiwan, Mongolia, North Korea, South Korea, Thailand, Papua New Guinea, Vietnam, Indonesia, Philippines, Malaysia, Russian Federation, Singapore, Hong Kong, and Macao.
• Royalty Structure: ASEP’s subsidiary ABT Innovations will earn a 10 % royalty on all oral‑rinse sales generated by Bondent.
• Development Responsibilities: Bondent to oversee formulation, clinical trials, regulatory filings, manufacturing scale‑up, marketing, and distribution through its dental clinic network and training platforms.
• Technology Description: Anti‑biofilm peptide designed to disrupt bacterial biofilms—responsible for ~65 % of infections—and currently has no FDA‑approved targeted therapies. Peptides have demonstrated anti‑biofilm and anti‑inflammatory activity in preclinical/early clinical studies.
• Strategic Rationale (CEO Quote): “This agreement… is a major milestone… creates a powerful partnership to address chronic oral biofilm infections that current products simply do not resolve.”
• Executive Change: Timothy Murphy will step down as COO, corporate secretary, and board member effective 31 Oct 2025; he will assume a board position at Sepset Biosciences to lead commercialization of the SepsetER sepsis diagnostic technology.
• Additional Quote (CEO): “We sincerely thank Timothy for his leadership… His deep understanding of licensing… makes him ideally positioned to accelerate SepsetER.”

Notable Quotes

• Dr. Robert Hancock, CEO: “This agreement with Bondent is a major milestone in our strategy to bring truly novel anti‑biofilm solutions to large global markets.”
• Timothy Murphy: “SepsetER has the potential to transform how sepsis is diagnosed and treated. I’m excited to dedicate my focus to bringing the SepsetER technology to market.”